Genewiz

Executive Summary

Genewiz, now operating under Azenta Life Sciences, is a global leader in genomics services, with laboratories in Germany and the UK. The company provides high-quality next-generation and Sanger sequencing, gene and oligo synthesis, and plasmid DNA preparation. It also offers regulated, GLP-compliant and CAP/CLIA-accredited preclinical and clinical services, supporting therapeutic, diagnostic, and agricultural product development. Founded in 1999 and headquartered in South Plainfield, New Jersey, Genewiz serves a broad customer base in academia, biotech, and pharma. Its integration with Azenta Life Sciences enhances its capabilities in sample management and genomic solutions. With a valuation around $1 billion and a strong reputation for quality and reliability, Genewiz is well-positioned to benefit from the growing demand for outsourced genomics services. The company's focus on high-throughput sequencing and synthetic biology aligns with key trends in personalized medicine and drug discovery.

Upcoming Catalysts (preview)

• Q3 2026Launch of new long-read sequencing service80% success
• Q4 2026Expansion of CLIA lab capacity for clinical trials70% success
• Q2 2026Strategic partnership with a top-20 pharma for genomic data analysis65% success